Alpha-ethyltryptamine

alpha-Ethyltryptamine (Etryptamine, α-ethyltryptamine, α-ET, or AET), is a psychoactive drug belonging to the tryptamine family. It was explored as an anti-depressant by Upjohn Chemical Company under the name Monase, but was withdrawn from commercial use after a year due to the unacceptable occurence of agranulocytosis. It was moved into US Schedule I list of illegal substances in 1993. It is structurally related to α-methyltryptamine but its pharmacological effects are very different. α-ET is not a hallucinogenic drug, its effects resemble more that of the empathogen-entactogens like MDMA (Ecstasy). Alexander Shulgin, in TiHKAL, mentions that this compound has been used to alleviate unpleasant symptoms of opiate withdrawal.

Dosage
75-150 mg is commonly consumed orally for entactogenic effects. α-ET has a stereocenter and S-(+)-α-ET is the more active stereoisomer.